ArticleFrontiers in neurology2021
Increased Autoimmunity in Individuals With Down Syndrome and Moyamoya Disease.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Association of moyamoya vasculopathy with autoimmune disease: a systematic review and pooled analysis.Neurosurgical review · 2023Pooled it
- Cardiovascular Disease Incidence and Risk Factors in Older Adults With Intellectual Disabilities: Results of the Healthy Ageing and Intellectual Disabilities Study.Journal of intellectual disability research : JIDR · 2025Article
- Construction and Analysis of Immune Infiltration and Competing Endogenous RNA Network in Moyamoya Disease.International journal of molecular sciences · 2025Article
- Alternative Diagnoses in the Work Up of Down Syndrome Regression Disorder.Journal of autism and developmental disorders · 2025Article
- Lipidomic profiling of the cerebrospinal fluid in moyamoya angiopathy patients.Orphanet journal of rare diseases · 2025Article
- Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder.Scientific reports · 2024Article
- Article
- Down Syndrome and Autoimmune Disease.Clinical reviews in allergy & immunology · 2024Review
- Article
- Case Report: A rare presentation of rapidly progressive moyamoya disease refractory to unilateral surgical revascularization.Frontiers in surgery · 2024Article
- Hypovitaminosis D in persons with Down syndrome and autism spectrum disorder.Journal of neurodevelopmental disorders · 2023Article
- Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder.Translational psychiatry · 2023Observational
- Immunotherapy Responsiveness and Risk of Relapse in Down Syndrome Regression Disorder.Research square · 2023Article
- Current Understanding of Moyamoya Disease (MMD) and Associated Neuropsychiatric Outcomes.Neuropsychiatric disease and treatment · 2023Review
- Case Report:Frontiers in pediatrics · 2023Article
- Moyamoya syndrome with ruptured aneurysm in α-thalassemia: A case report.Experimental and therapeutic medicine · 2022Article
- Moyamoya syndrome in a young person with Down syndrome: diagnostic and therapeutic considerations.BMJ case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.